MCID: PRR013
MIFTS: 35

Prurigo Nodularis malady

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Prurigo Nodularis

Aliases & Descriptions for Prurigo Nodularis:

Name: Prurigo Nodularis 50 52 69

Classifications:



External Ids:

ICD10 33 L28.1

Summaries for Prurigo Nodularis

NIH Rare Diseases : 50 prurigo nodularis is a skin condition characterized by hard crusty lumps that itch intensely.  the exact cause of the condition is unknown. however, it can occur in isolation or as a result of repeated trauma to chronic pruritus (itching). treatment for the condition can be challenging. last updated: 12/30/2015

MalaCards based summary : Prurigo Nodularis is related to dermatitis and lymphoma. An important gene associated with Prurigo Nodularis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Phospholipase-C Pathway and p70S6K Signaling. The drugs Nalbuphine and Peripheral Nervous System Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, tonsil and neutrophil.

Wikipedia : 71 Prurigo nodularis (PN) is a skin disease characterised by pruritic (itchy) nodules which usually appear... more...

Related Diseases for Prurigo Nodularis

Diseases related to Prurigo Nodularis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
id Related Disease Score Top Affiliating Genes
1 dermatitis 10.2
2 lymphoma 10.1
3 marasmus 10.1 NGF RNASE3
4 appendix carcinoid tumor 10.1 NGF RNASE3
5 hypermobility of coccyx 10.1 NGF NGFR
6 lymphangiectasia, intestinal 10.1 NGF RNASE3
7 respiratory failure 10.1 NGF NGFR
8 tracheitis 10.1 NGF RNASE3
9 hepatitis 10.1
10 tonsillitis 10.1
11 bullous pemphigoid 10.1
12 dilated cardiomyopathy 10.0 NGF NGFR
13 placenta accreta 10.0 RNASE3 TAC1
14 malignant renovascular hypertension 10.0 NGF TAC1
15 eyelid neoplasm 10.0 RNASE3 TAC1
16 glucocorticoid resistance 10.0 NGF RNASE3
17 neuropathy 10.0
18 hodgkin lymphoma 10.0
19 lichen planus 10.0
20 keratoacanthoma 10.0
21 neurodermatitis 10.0
22 uremia 10.0
23 herpes zoster 10.0
24 tinea capitis 10.0 NGF TAC1
25 hemopericardium 10.0 NGF TAC1
26 generalized epilepsy with febrile seizures plus 10.0 NGF TAC1
27 acquired polycythemia 10.0 RNASE3 TAC1
28 testicular leydig cell tumor 10.0 NGF TAC1
29 uterine corpus dissecting leiomyoma 10.0 NGF TAC1
30 xanthogranulomatous cholecystitis 10.0 RNASE3 TAC1
31 brain injury 9.9 NGF TAC1
32 uterine ligament serous adenocarcinoma 9.9 NGF TAC1
33 corneal ulcer 9.9 SEMA3A TAC1
34 familial renal papillary carcinoma 9.9 RNASE3 TAC1
35 angioedema 9.9 RNASE3 TAC1
36 neovascular glaucoma 9.9 NGF TAC1
37 spontaneous ocular nystagmus 9.9 RNASE3 TAC1
38 acute chest syndrome 9.9 RNASE3 TAC1
39 malignant peritoneal solitary fibrous tumor 9.9 NGF RNASE3
40 atopy 9.8
41 transitional cell carcinoma 9.8
42 hashimoto thyroiditis 9.8
43 psoriasis 9.8
44 contact dermatitis 9.8
45 amyloidosis 9.8
46 celiac disease 9.8
47 allergic contact dermatitis 9.8
48 burns 9.8
49 cytomegalic inclusion disease 9.8
50 gastric cancer 9.8

Graphical network of the top 20 diseases related to Prurigo Nodularis:



Diseases related to Prurigo Nodularis

Symptoms & Phenotypes for Prurigo Nodularis

Drugs & Therapeutics for Prurigo Nodularis

Drugs for Prurigo Nodularis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nalbuphine Approved Phase 2, Phase 3 20594-83-6 5360630 5311304
2 Peripheral Nervous System Agents Phase 2, Phase 3
3 Analgesics Phase 2, Phase 3
4 Narcotic Antagonists Phase 2, Phase 3
5 Narcotics Phase 2, Phase 3
6 Analgesics, Opioid Phase 2, Phase 3
7 Central Nervous System Depressants Phase 2, Phase 3
8 Antipruritics Phase 2, Phase 3
9
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
10
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
11
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 6447131 17753757
12
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
13
Butyric Acid Experimental Phase 2 107-92-6 264
14
Substance P Investigational Phase 2 33507-63-0 44359816
15 Neurotransmitter Agents Phase 2
16 neurokinin A Phase 2
17 Serlopitant Phase 2
18 Neurokinin-1 Receptor Antagonists Phase 2
19 Cortisol succinate Phase 2
20 Analgesics, Non-Narcotic Phase 2
21 Dermatologic Agents Phase 2
22 Angiogenesis Inhibitors Phase 2
23 Angiogenesis Modulating Agents Phase 2
24 Hydrocortisone 17-butyrate 21-propionate Phase 2
25 Hydrocortisone acetate Phase 2
26 Hydrocortisone-17-butyrate Phase 2
27 Anti-Bacterial Agents Phase 2
28 Anti-Infective Agents Phase 2
29 Immunosuppressive Agents Phase 2
30 Anti-Inflammatory Agents Phase 2
31 Anti-Inflammatory Agents, Non-Steroidal Phase 2
32 Antirheumatic Agents Phase 2
33 Calcineurin Inhibitors Phase 2
34
Citalopram Approved 59729-33-8 2771
35
Dapsone Approved, Investigational 80-08-0 2955
36
leucovorin Approved, Nutraceutical 58-05-9 54575, 6560146 143
37
Folic Acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
38
Serotonin 50-67-9 5202
39 Muscarinic Antagonists
40 Cholinergic Agents
41 Cholinergic Antagonists
42 Serotonin Agents
43 Serotonin Uptake Inhibitors
44 Neurotransmitter Uptake Inhibitors
45 Parasympatholytics
46 Antidepressive Agents
47 Antidepressive Agents, Second-Generation
48 Psychotropic Drugs
49 Autonomic Agents
50 Antiparkinson Agents

Interventional clinical trials:


id Name Status NCT ID Phase
1 Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis Completed NCT02174419 Phase 2, Phase 3
2 Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis Active, not recruiting NCT02174432 Phase 2, Phase 3
3 A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) Completed NCT02196324 Phase 2
4 Safety and Efficacy of CC-10004 for Prurigo Nodularis Completed NCT00869089 Phase 2
5 Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Completed NCT00507832 Phase 2
6 Safety and Efficacy of Nemolizumab in PN Not yet recruiting NCT03181503 Phase 2
7 Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis Unknown status NCT00532519
8 Dapsone Prurigo Study Not yet recruiting NCT01870050

Search NIH Clinical Center for Prurigo Nodularis

Genetic Tests for Prurigo Nodularis

Anatomical Context for Prurigo Nodularis

MalaCards organs/tissues related to Prurigo Nodularis:

39
Skin, Tonsil, Neutrophil, Endothelial, T Cells, Thyroid, Testes

Publications for Prurigo Nodularis

Articles related to Prurigo Nodularis:

(show top 50) (show all 175)
id Title Authors Year
1
Prurigo Nodularis Management. ( 27578077 )
2016
2
Aspirin and loxoprofen relieve refractory pruritus in patients with prurigo nodularis. ( 26970197 )
2016
3
Treatment of prurigo nodularis with dexamethasone-cyclophosphamide pulse therapy. ( 26858054 )
2016
4
Phototherapy for the treatment of prurigo nodularis: a review. ( 27617458 )
2016
5
Acquired Reactive Perforating Dermatosis is a Variant of Prurigo Nodularis. ( 27349279 )
2016
6
Systemic methotrexate for prurigo nodularis and keratoacanthomas in actinically damaged skin. ( 27486591 )
2016
7
A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis. ( 27289372 )
2016
8
Bullous pemphigoid developed in a patient with prurigo nodularis. ( 27511319 )
2016
9
Hypertrophic lichen planus versus prurigo nodularis: a dermoscopic perspective. ( 27222766 )
2016
10
Anxiety, depression and suicide in patients with prurigo nodularis. ( 27505149 )
2016
11
Treatment of prurigo nodularis with dexamethasone-cyclophosphamide pulse therapy. ( 26924412 )
2016
12
Treatment of prurigo nodularis with lenalidomide. ( 27891738 )
2016
13
Dermoscopy of prurigo nodularis. ( 25808786 )
2015
14
Oral Tacrolimus Treatment of Pruritus in Prurigo Nodularis. ( 25804254 )
2015
15
The pathogenesis of Prurigo nodularis - 'Super-Itch' in exploration. ( 26416433 )
2015
16
Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis. ( 25497953 )
2015
17
Prurigo nodularis after acupuncture. ( 27051775 )
2015
18
Intraepidermal Nerve Fibre Density is Decreased in Lesional and Inter-lesional Prurigo Nodularis and Reconstitutes on Healing of Lesions. ( 26338533 )
2015
19
Prurigo nodularis: Picking the right treatment. ( 25973448 )
2015
20
Serotonin and interleukin-6: Association with pruritus severity, sleep quality and depression severity in Prurigo Nodularis. ( 26277226 )
2015
21
Biopsychosocial Factors Associated with Prurigo Nodularis in Endogenous Eczema. ( 26538749 )
2015
22
Intractable prurigo nodularis successfully treated with combination therapy with a newly developed excimer laser and topical steroids. ( 24945654 )
2014
23
Persistent prurigo nodularis in HIV-infected patient responsive to antiretroviral therapy with raltegravir. ( 24479440 )
2014
24
Prurigo nodularis as index symptom of (non-Hodgkin) lymphoma: ultrasound as a helpful diagnostic tool in dermatological disorders of unknown origin. ( 24697249 )
2014
25
Extensive prurigo nodularis: characterization and etiology. ( 24662043 )
2014
26
Prurigo nodularis and Hashimoto thyroiditis. ( 25446192 )
2014
27
Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. ( 24825138 )
2014
28
Paraphenylenediamine dye allergic contact dermatitis of mustache region manifesting as prurigo nodularis-like lesions. ( 24603506 )
2014
29
Prurigo nodularis in a peritoneal dialysis patient. ( 24380918 )
2014
30
Evaluation of the Antipruritic Effects of Topical Pimecrolimus in Non-Atopic Prurigo Nodularis: Results of a Randomized, Hydrocortisone-Controlled, Double-Blind Phase II Trial. ( 24281309 )
2013
31
Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis. ( 24102897 )
2013
32
Aberrant epidermal expression of semaphorin 3A and nerve growth factor in prurigo nodularis. ( 23398122 )
2013
33
Prurigo nodularis and dialyzer membrane. ( 23676832 )
2013
34
Linear IgA bullous dermatosis with a prurigo nodularis-like appearance. ( 23306219 )
2013
35
Use of lenalidomide in treating refractory prurigo nodularis. ( 23545923 )
2013
36
Prurigo nodularis-like skin eruptions in a patient with IgG4-related disease. ( 24001614 )
2013
37
Oral ketotifen and topical antibiotic therapy in the management of pruritus in prurigo nodularis: a randomized, controlled, single-blind, parallel study. ( 24082179 )
2013
38
Prurigo nodularis: an update on etiopathogenesis and therapy. ( 23767411 )
2013
39
Treatment of prurigo nodularis with pregabalin. ( 23013514 )
2013
40
Successful treatment of chronic intractable itching using oral pregabalin in a patient with diabetes and systemic prurigo nodularis: a case report of an iliopsoas muscle abscess. ( 24292753 )
2013
41
Prurigo nodularis in hepatitis C infection: result of an occupational disease? ( 22002555 )
2012
42
Accidental PUVA burns, vitiligo and atopic diathesis resulting in prurigo nodularis: a logical but undocumented rarity. ( 23197209 )
2012
43
Treatment of refractory prurigo nodularis with lenalidomide. ( 22801610 )
2012
44
Atopic prurigo nodularis responds to intravenous immunoglobulins. ( 21910702 )
2012
45
Prurigo nodularis as the first manifestation of a chronic autoimmune cholestatic hepatitis. ( 22098015 )
2011
46
Psychological factors involved in prurigo nodularis: A pilot study. ( 20666670 )
2011
47
Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. ( 21711341 )
2011
48
Parthenium dermatitis manifesting clinically as polymorphic light eruption and prurigo nodularis- like lesions with vasculitis-like picture on histopathology. ( 23130236 )
2011
49
Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. ( 21410670 )
2011
50
Efficacy of thalidomide in the treatment of prurigo nodularis. ( 21279302 )
2011

Variations for Prurigo Nodularis

Expression for Prurigo Nodularis

Search GEO for disease gene expression data for Prurigo Nodularis.

Pathways for Prurigo Nodularis

GO Terms for Prurigo Nodularis

Cellular components related to Prurigo Nodularis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.02 NGF NGFR RNASE3 SEMA3A TAC1

Biological processes related to Prurigo Nodularis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.37 NGF NGFR
2 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.32 NGF NGFR
3 negative regulation of neuron projection development GO:0010977 9.26 NGFR SEMA3A
4 positive regulation of axonogenesis GO:0050772 9.16 NGF NGFR
5 neurotrophin TRK receptor signaling pathway GO:0048011 8.96 NGF NGFR
6 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 8.62 NGF NGFR

Sources for Prurigo Nodularis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....